Youjie Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Youjie Zeng has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Si Cao
Department of Anesthesiology Third Xiangya Hospital, Central South University Changsha Hunan China
17 shared publications- Heng Yang
Department of Neurology, Third Xiangya Hospital, Central South University, Changsha, China
8 shared publications - Michael E. Belloy
Washington University in St. Louis
8 shared publications - Chenyu Yang
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA
7 shared publications - Noah Cook
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
7 shared publications - Carlos Cruchaga
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA
6 shared publications
Latest Publications
- Open Access
LocusBlend: Flexible multi-index regional visualization of genomic association signals
Summary: It has become standard practice to visualize regional signals from genome-wide association studies (GWAS) using LocusZoom plots. Similarly, GWAS signals are compared to regionally matched quantitative trait loci (QTLs), i.e. variant-to-gene regulation data, using LocusCompare plots to aid assessment of candidate trait-related genes. Despite broad usage, these tools annotate variants by linkage disequilibrium (LD) to a single lead or index variant. This single-index representation has limitations for visualizing complex loci that contain multiple independent signals. We present LocusBlend, an interactive web application for multi-index LD-blended visualization of genomic loci. LocusBlend supports one or two genomic association summary-statistic datasets and one to three index variants, multi-index LocusZoom color-blended plots, and matching LocusCompare visualizations. Applications to Alzheimer’s disease GWAS and QTL signals illustrate LocusBlend enables visualization and separation of independent signals despite shared LD and high genomic complexity. Overall, LocusBlend is aimed at supporting researchers handle the continuously expanding complexity of human genomics findings. Availability and Implementation: LocusBlend is freely available at https://locusblend.wustl.edu . Publication ready plots are generated in <1min. Source code, documentation, example datasets, input templates, and reproducibility instructions are available at https://github.com/Belloy-Lab/LocusBlend . LocusBlend is implemented in Python using Streamlit, Plotly, and PLINK. Supplementary Information: Supplementary data are available at Bioinformatics online.
Open AccessLocusBlend: Flexible multi-index regional visualization of genomic association signals
Summary: It has become standard practice to visualize regional signals from genome-wide association studies (GWAS) using LocusZoom plots. Similarly, GWAS signals are compared to regionally matched quantitative trait loci (QTLs), i.e. variant-to-gene regulation data, using LocusCompare plots to aid assessment of candidate trait-related genes. Despite broad usage, these tools annotate variants by linkage disequilibrium (LD) to a single lead or index variant. This single-index representation has limitations for visualizing complex loci that contain multiple independent signals. We present LocusBlend, an interactive web application for multi-index LD-blended visualization of genomic loci. LocusBlend supports one or two genomic association summary-statistic datasets and one to three index variants, multi-index LocusZoom color-blended plots, and matching LocusCompare visualizations. Applications to Alzheimer’s disease GWAS and QTL signals illustrate LocusBlend enables visualization and separation of independent signals despite shared LD and high genomic complexity. Overall, LocusBlend is aimed at supporting researchers handle the continuously expanding complexity of human genomics findings. Availability and Implementation: LocusBlend is freely available at https://locusblend.wustl.edu . Publication ready plots are generated in <1min. Source code, documentation, example datasets, input templates, and reproducibility instructions are available at https://github.com/Belloy-Lab/LocusBlend . LocusBlend is implemented in Python using Streamlit, Plotly, and PLINK. Supplementary Information: Supplementary data are available at Bioinformatics online.
- Open Access
geneXplore: An Interactive Browser for X Chromosome-Wide Association Study Results
Summary: The X chromosome comprises approximately 5% of the human genome and encodes over 800 protein-coding genes, many of which exhibit sex-differentiated expression patterns due to escape from X chromosome inactivation (XCI) mechanisms. Despite its relevance to sex differences in complex traits, the X chromosome is routinely excluded from genome-wide association studies due to analytical challenges, and when analyzed, the impact of escape from XCI or sex is limitedly explored. No dedicated, publicly accessible browser for X chromosome-wide association study (XWAS) summary statistics currently exists, creating a barrier to systematic investigation of X-linked contributions to human traits. Here, we present geneXplore, an interactive web browser based on the PheWeb2 implementation, tailored for XWAS summary statistics across 1,944 phenotypes while distinguishing random XCI (rXCI), escape from XCI (eXCI), and sex-stratified analyses. Users can explore results via interactive plots (Manhattan and Miami, PheWAS and LocusZoom), searchable tables and access to cross-database lookup, with full summary statistics available for download. Availability and Implementation: geneXplore is freely available at https://genexplore.wustl.edu/ with no registration required and will be maintained for a minimum of two years following publication. Source code is available at https://github.com/Belloy-Lab/geneXplore_XWAS_Browser under an MIT license.
Open AccessgeneXplore: An Interactive Browser for X Chromosome-Wide Association Study Results
Summary: The X chromosome comprises approximately 5% of the human genome and encodes over 800 protein-coding genes, many of which exhibit sex-differentiated expression patterns due to escape from X chromosome inactivation (XCI) mechanisms. Despite its relevance to sex differences in complex traits, the X chromosome is routinely excluded from genome-wide association studies due to analytical challenges, and when analyzed, the impact of escape from XCI or sex is limitedly explored. No dedicated, publicly accessible browser for X chromosome-wide association study (XWAS) summary statistics currently exists, creating a barrier to systematic investigation of X-linked contributions to human traits. Here, we present geneXplore, an interactive web browser based on the PheWeb2 implementation, tailored for XWAS summary statistics across 1,944 phenotypes while distinguishing random XCI (rXCI), escape from XCI (eXCI), and sex-stratified analyses. Users can explore results via interactive plots (Manhattan and Miami, PheWAS and LocusZoom), searchable tables and access to cross-database lookup, with full summary statistics available for download. Availability and Implementation: geneXplore is freely available at https://genexplore.wustl.edu/ with no registration required and will be maintained for a minimum of two years following publication. Source code is available at https://github.com/Belloy-Lab/geneXplore_XWAS_Browser under an MIT license.
- Open Access
Sex-biased Genetic Risk Loci and Causal Brain Proteins in Parkinson's Disease
Parkinson's disease (PD) exhibits pronounced sex differences, yet the underlying genetic and molecular mechanisms remain poorly understood. We performed the largest-to-date meta-analysis of sex-stratified genome-wide association studies of PD followed by brain proteogenomics-based causal inference analyses. We nominated 10 candidate proteins that appear important to sex-biased PD risk, of which 2 female-biased, GALC and PSMG1, and 3 male-biased, ACTR1B, WDR41, and CD151, were most robustly prioritized. Together, our findings provide evidence for genetic sex differences in PD, prioritizing sex-biased proteins implicated in lysosomal regulation, neuroinflammation, lipid biology, and other PD-relevant mechanisms, and highlighting potential sex-informed therapeutic opportunities.
Open AccessSex-biased Genetic Risk Loci and Causal Brain Proteins in Parkinson's Disease
Parkinson's disease (PD) exhibits pronounced sex differences, yet the underlying genetic and molecular mechanisms remain poorly understood. We performed the largest-to-date meta-analysis of sex-stratified genome-wide association studies of PD followed by brain proteogenomics-based causal inference analyses. We nominated 10 candidate proteins that appear important to sex-biased PD risk, of which 2 female-biased, GALC and PSMG1, and 3 male-biased, ACTR1B, WDR41, and CD151, were most robustly prioritized. Together, our findings provide evidence for genetic sex differences in PD, prioritizing sex-biased proteins implicated in lysosomal regulation, neuroinflammation, lipid biology, and other PD-relevant mechanisms, and highlighting potential sex-informed therapeutic opportunities.
- Open Access
- 22 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71552
APOE *4 risk‐modifying genes and drug targets in Alzheimer's disease through cell‐type‐specific genomic analyses
INTRODUCTION: Genetics studies can identify drug targets that counteract the effects of the apolipoprotein E ε4 allele ( APOE *4) on Alzheimer's disease (AD) but have remained limited in power and crucially did not assess genetic findings with regard to APOE *4's cell‐type‐specific impact on pathobiology. METHODS: We conducted a novel APOE *4‐stratified genome‐wide association study (GWAS) of AD ( N = 447,669) and integrated results with brain cell‐type‐specific multi‐omics data to identify APOE *4 and cell‐type‐specific AD genes, followed by compound and drug repurposing. RESULTS: In APOE *4 non‐carriers ( APOE *4−) and carriers ( APOE *4+), we respectively identified 33 and 11 cell type–gene pairs with strong prioritization support. Oligodendrocytes displayed the largest proportion of APOE *4+ genes. Several genes were druggable and pinpointed APOE *4‐stratified drugs or compounds. DISCUSSION: We identified a set of APOE *4‐stratified genes that may be causal for AD through brain cell‐type‐specific mechanisms. We additionally identified compounds that may shed light on therapeutic avenues for treating AD based on an individual's APOE *4 status.
- 22 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71552
Open AccessAPOE *4 risk‐modifying genes and drug targets in Alzheimer's disease through cell‐type‐specific genomic analyses
INTRODUCTION: Genetics studies can identify drug targets that counteract the effects of the apolipoprotein E ε4 allele ( APOE *4) on Alzheimer's disease (AD) but have remained limited in power and crucially did not assess genetic findings with regard to APOE *4's cell‐type‐specific impact on pathobiology. METHODS: We conducted a novel APOE *4‐stratified genome‐wide association study (GWAS) of AD ( N = 447,669) and integrated results with brain cell‐type‐specific multi‐omics data to identify APOE *4 and cell‐type‐specific AD genes, followed by compound and drug repurposing. RESULTS: In APOE *4 non‐carriers ( APOE *4−) and carriers ( APOE *4+), we respectively identified 33 and 11 cell type–gene pairs with strong prioritization support. Oligodendrocytes displayed the largest proportion of APOE *4+ genes. Several genes were druggable and pinpointed APOE *4‐stratified drugs or compounds. DISCUSSION: We identified a set of APOE *4‐stratified genes that may be causal for AD through brain cell‐type‐specific mechanisms. We additionally identified compounds that may shed light on therapeutic avenues for treating AD based on an individual's APOE *4 status.
- Open Access
An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer’s Disease
The genetic contributions of the X chromosome to Alzheimer’s disease (AD) remain poorly understood yet are expected to importantly shape sex differences in AD. We therefore performed large-scale X-chromosome-wide association studies (N=1,240,451), evaluating differential risk due to sex, APOE *4, and escape from X-chromosome inactivation, finding most X-linked loci appear relevant to female-biased AD etiology. In evaluating genetic pleiotropy with hormonal, lipid, and brain imaging traits, we discovered X-linked AD loci converged on white matter traits, particularly in the anterior corona radiata and splenium of the corpus callosum. Through brain-centric functional genomics analyses, we then nominated candidate causal genes, including 5 that appeared highly robust. Notably, we found the escape gene RBBP7 decreases AD risk in APOE *4 carriers likely through higher expression in excitatory neurons to counter tau-related neurodegeneration. Altogether, we provide an atlas of sex and APOE *4-informed candidate X-linked AD risk loci, genes, and mechanisms that will guide future studies.
Open AccessAn APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer’s Disease
The genetic contributions of the X chromosome to Alzheimer’s disease (AD) remain poorly understood yet are expected to importantly shape sex differences in AD. We therefore performed large-scale X-chromosome-wide association studies (N=1,240,451), evaluating differential risk due to sex, APOE *4, and escape from X-chromosome inactivation, finding most X-linked loci appear relevant to female-biased AD etiology. In evaluating genetic pleiotropy with hormonal, lipid, and brain imaging traits, we discovered X-linked AD loci converged on white matter traits, particularly in the anterior corona radiata and splenium of the corpus callosum. Through brain-centric functional genomics analyses, we then nominated candidate causal genes, including 5 that appeared highly robust. Notably, we found the escape gene RBBP7 decreases AD risk in APOE *4 carriers likely through higher expression in excitatory neurons to counter tau-related neurodegeneration. Altogether, we provide an atlas of sex and APOE *4-informed candidate X-linked AD risk loci, genes, and mechanisms that will guide future studies.
- Open Access
Massive-scale single-nucleus multi-omics identifies novel rare noncoding drivers of Parkinson’s disease
Most genetic variants contributing to complex diseases reside in the noncoding genome. While common variants uncovered by genome-wide association studies often fail to explain much of the observed heritability of these diseases, rare variants often have higher effect sizes and cumulatively explain a larger portion of heritability. However, rare variants, particularly rare noncoding variants, have remained under-characterized largely due to the difficulties of accurately predicting variant functionality at scale, given that each individual carries an average of ∼10,000 rare variants. Here, we generated multi-omic data from >3.3 million nuclei sampled from five brain regions across a cohort of 80 individuals with Parkinson’s disease (PD) and 21 neurologically normal control individuals with matched 30x whole-genome sequencing. We use this data to identify cell type-specific features of PD, map cell type-specific chromatin accessibility and expression quantitative trait loci, and train machine learning models to predict the effect of variants on gene regulation. We identify rare noncoding variants statistically associated with sporadic PD and extend our approaches to predict drivers of familial PD of unknown genetic origin. Our results underscore the significance of rare noncoding variants in complex diseases and provide a roadmap for applying similar approaches in other disease systems.
Open AccessMassive-scale single-nucleus multi-omics identifies novel rare noncoding drivers of Parkinson’s disease
Most genetic variants contributing to complex diseases reside in the noncoding genome. While common variants uncovered by genome-wide association studies often fail to explain much of the observed heritability of these diseases, rare variants often have higher effect sizes and cumulatively explain a larger portion of heritability. However, rare variants, particularly rare noncoding variants, have remained under-characterized largely due to the difficulties of accurately predicting variant functionality at scale, given that each individual carries an average of ∼10,000 rare variants. Here, we generated multi-omic data from >3.3 million nuclei sampled from five brain regions across a cohort of 80 individuals with Parkinson’s disease (PD) and 21 neurologically normal control individuals with matched 30x whole-genome sequencing. We use this data to identify cell type-specific features of PD, map cell type-specific chromatin accessibility and expression quantitative trait loci, and train machine learning models to predict the effect of variants on gene regulation. We identify rare noncoding variants statistically associated with sporadic PD and extend our approaches to predict drivers of familial PD of unknown genetic origin. Our results underscore the significance of rare noncoding variants in complex diseases and provide a roadmap for applying similar approaches in other disease systems.
- Open Access
APOE *4 Risk-Modifying Genes and Drug Targets in Alzheimer’s Disease through Cell-Type Specific Genomic Analyses
Importance: APOE *4 is the strongest, common genetic risk factor for late-onset Alzheimer’s disease (AD) with widespread and cell-type-specific impact on disease pathogenesis. Genetics and omics studies can help identify genes that counteract the effects of APOE *4, but so far have remained relatively small and crucially did not assess genetic findings through a cell-type-specific framework. Objectives: Perform a large-scale APOE *4 stratified genome-wide association study (GWAS) of AD integrated with genetically tethered cell-type-specific multi-omics data. Design: Meta-analysis of APOE *4 stratified AD GWAS in case-control, family-based, population-based, and longitudinal AD-related cohorts from the Alzheimer’s Disease Genetics Consortium, Alzheimer’s Disease Sequencing Project, and UK Biobank. Integration of GWAS with brain cell-type-specific genetic regulation of gene expression data, from the Religious Orders Study and Memory and Aging Project, to identify APOE *4 and cell-type-specific AD genes. Cell-type-specific multi-omics gene prioritization followed by compound and drug repurposing. Data analyzed between January 2023 and September 2025. Setting: Genetic data available from high-density single-nucleotide polymorphism (SNP) microarrays and whole-genome sequencing (WGS). Single-nucleus (sn) RNA-seq data from dorsolateral prefrontal cortex. Participants: 567,521 eligible participants for AD genetic association studies were selected from referred and volunteer samples, of which 119,852 were excluded for analysis exclusion criteria. Main Outcome and Measures: APOE *4 and cell-type-specific gene Z-scores and FDR-corrected P-values. Gene prioritization scores and APOE *4 stratified enriched compounds. Results: 67 and 17 significant cell-type-gene pairs were identified in APOE *4 non-carriers ( APOE *4-) and carriers ( APOE *4+) respectively. Oligodendrocytes displayed the largest proportion of APOE *4+ genes. 46 cell-type-gene pairs were supported by at least half of the gene prioritization analyses. Several prioritized genes were druggable and displayed enrichment of APOE *4 stratified drugs or compounds. Top APOE *4+ genes with connections to enriched drugs or compounds included TNS3 (astrocytes), CISD1 and SLC23A2 (oligodendrocytes), and UBXN4 (excitatory neurons). Conclusion and Relevance: We identified a set of APOE *4 stratified genes that may be causal for AD through brain cell-type-specific mechanisms and prioritized top genes for further interrogation. We additionally identified compounds that may be repurposed or shed light on therapeutic avenues for treating AD based on an individual’s APOE *4 status. Top identified compounds such as Hydrocortisone and Trolox implicate oxidative stress and neuroinflammation as potential biological targets in APOE *4+ individuals.
Open AccessAPOE *4 Risk-Modifying Genes and Drug Targets in Alzheimer’s Disease through Cell-Type Specific Genomic Analyses
Importance: APOE *4 is the strongest, common genetic risk factor for late-onset Alzheimer’s disease (AD) with widespread and cell-type-specific impact on disease pathogenesis. Genetics and omics studies can help identify genes that counteract the effects of APOE *4, but so far have remained relatively small and crucially did not assess genetic findings through a cell-type-specific framework. Objectives: Perform a large-scale APOE *4 stratified genome-wide association study (GWAS) of AD integrated with genetically tethered cell-type-specific multi-omics data. Design: Meta-analysis of APOE *4 stratified AD GWAS in case-control, family-based, population-based, and longitudinal AD-related cohorts from the Alzheimer’s Disease Genetics Consortium, Alzheimer’s Disease Sequencing Project, and UK Biobank. Integration of GWAS with brain cell-type-specific genetic regulation of gene expression data, from the Religious Orders Study and Memory and Aging Project, to identify APOE *4 and cell-type-specific AD genes. Cell-type-specific multi-omics gene prioritization followed by compound and drug repurposing. Data analyzed between January 2023 and September 2025. Setting: Genetic data available from high-density single-nucleotide polymorphism (SNP) microarrays and whole-genome sequencing (WGS). Single-nucleus (sn) RNA-seq data from dorsolateral prefrontal cortex. Participants: 567,521 eligible participants for AD genetic association studies were selected from referred and volunteer samples, of which 119,852 were excluded for analysis exclusion criteria. Main Outcome and Measures: APOE *4 and cell-type-specific gene Z-scores and FDR-corrected P-values. Gene prioritization scores and APOE *4 stratified enriched compounds. Results: 67 and 17 significant cell-type-gene pairs were identified in APOE *4 non-carriers ( APOE *4-) and carriers ( APOE *4+) respectively. Oligodendrocytes displayed the largest proportion of APOE *4+ genes. 46 cell-type-gene pairs were supported by at least half of the gene prioritization analyses. Several prioritized genes were druggable and displayed enrichment of APOE *4 stratified drugs or compounds. Top APOE *4+ genes with connections to enriched drugs or compounds included TNS3 (astrocytes), CISD1 and SLC23A2 (oligodendrocytes), and UBXN4 (excitatory neurons). Conclusion and Relevance: We identified a set of APOE *4 stratified genes that may be causal for AD through brain cell-type-specific mechanisms and prioritized top genes for further interrogation. We additionally identified compounds that may be repurposed or shed light on therapeutic avenues for treating AD based on an individual’s APOE *4 status. Top identified compounds such as Hydrocortisone and Trolox implicate oxidative stress and neuroinflammation as potential biological targets in APOE *4+ individuals.
- Open Access
Integrative Genetic, Proteogenomic, and Multi-omics Analyses Reveal Sex-Biased Causal Genes and Drug Targets in Alzheimer’s Disease
Sex differences are pervasive in Alzheimer’s disease, but the underlying drivers remain poorly understood. To address this, we performed sex-stratified genome-wide association studies of Alzheimer’s disease in ∼1,000,000 individuals, which we subsequently integrated with proteogenomics datasets from neurological tissues to identify candidate causal genes. We further prioritized genes through additional multi-omics approaches, including quantitative trait locus summary-based mendelian randomization and colocalization. Altogether, we prioritized 125 female-biased and 21 male-biased risk genes. Female-biased pathways included amyloid, neurite, stress, clearance, and immune processes, with genes enriched for microglia and astrocyte expression. Through computational drug repurposing analyses, a set of sex hormone related drugs, converging on Epidermal Growth Factor Receptor ( EGFR ), were uniquely prioritized in women. Finally, we identified Haptoglobin ( HP ) as a female-specific gene, leveraging long-read sequencing approaches to implicate a link to oxidative stress, APOE, and hemoglobin biology. Altogether, our findings provide a portal into sex-specific precision medicine for Alzheimer’s disease.
Open AccessIntegrative Genetic, Proteogenomic, and Multi-omics Analyses Reveal Sex-Biased Causal Genes and Drug Targets in Alzheimer’s Disease
Sex differences are pervasive in Alzheimer’s disease, but the underlying drivers remain poorly understood. To address this, we performed sex-stratified genome-wide association studies of Alzheimer’s disease in ∼1,000,000 individuals, which we subsequently integrated with proteogenomics datasets from neurological tissues to identify candidate causal genes. We further prioritized genes through additional multi-omics approaches, including quantitative trait locus summary-based mendelian randomization and colocalization. Altogether, we prioritized 125 female-biased and 21 male-biased risk genes. Female-biased pathways included amyloid, neurite, stress, clearance, and immune processes, with genes enriched for microglia and astrocyte expression. Through computational drug repurposing analyses, a set of sex hormone related drugs, converging on Epidermal Growth Factor Receptor ( EGFR ), were uniquely prioritized in women. Finally, we identified Haptoglobin ( HP ) as a female-specific gene, leveraging long-read sequencing approaches to implicate a link to oxidative stress, APOE, and hemoglobin biology. Altogether, our findings provide a portal into sex-specific precision medicine for Alzheimer’s disease.
- Open Access
- 18 September 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (9) , e70998
Breakfast Skipping Increases the Risk of Coronary Heart Disease and Myocardial Infarction: Evidence From the Mendelian Randomization Study
Observational studies have suggested a potential association between breakfast skipping and the risk of coronary heart disease (CHD) and myocardial infarction (MI). Nevertheless, due to potential confounders and reverse causation, the causal relationship remains unclear. This study aims to comprehensively assess the causal effect of breakfast skipping on CHD and MI through a two‐sample Mendelian randomization (MR) analysis. Genome‐wide summary statistics of breakfast skipping, CHD, and MI were obtained from public databases. Instrument variables (IVs) proxying for breakfast skipping were screened based on strict ( p < 5e−8) and lenient ( p < 1e−5) thresholds. Quality control of IVs was performed using Cochran's Q test, MR‐Egger intercept test, and MR PRESSO global test. Inverse variance weighted (IVW) served as the primary MR method for assessing causal associations, while MR‐Egger, weighted median, and maximum likelihood were used as supplementary methods. The effect of breakfast skipping on CHD and MI in both CARDIoGRAMplusC4D and FinnGen cohorts was assessed, and the results were integrated using meta‐analysis. Quality control tests showed no heterogeneity or horizontal pleiotropy in IVs. After conducting a meta‐analysis of the MR results from the IVW method under strict IV screening thresholds, breakfast skipping significantly increases the risk of CHD [odds ratio (OR) = 1.358, p = 3.95E−02] and MI (OR = 1.449, p = 4.17E−02). Similarly, meta‐analysis of the IVW results under lenient IV screening thresholds also demonstrated the detrimental effects of breakfast skipping on CHD (OR = 1.198, p = 5.55E−03) and MI (OR = 1.378, p = 4.08E−05). Three other MR methods showed parallel results to IVW (OR > 1). Overall, the present study demonstrates that breakfast skipping significantly increases the risk of CHD and MI. Therefore, maintaining a high‐quality breakfast intake can be considered an essential primary prevention measure for CHD and MI.
- 18 September 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (9) , e70998
Open AccessBreakfast Skipping Increases the Risk of Coronary Heart Disease and Myocardial Infarction: Evidence From the Mendelian Randomization Study
Observational studies have suggested a potential association between breakfast skipping and the risk of coronary heart disease (CHD) and myocardial infarction (MI). Nevertheless, due to potential confounders and reverse causation, the causal relationship remains unclear. This study aims to comprehensively assess the causal effect of breakfast skipping on CHD and MI through a two‐sample Mendelian randomization (MR) analysis. Genome‐wide summary statistics of breakfast skipping, CHD, and MI were obtained from public databases. Instrument variables (IVs) proxying for breakfast skipping were screened based on strict ( p < 5e−8) and lenient ( p < 1e−5) thresholds. Quality control of IVs was performed using Cochran's Q test, MR‐Egger intercept test, and MR PRESSO global test. Inverse variance weighted (IVW) served as the primary MR method for assessing causal associations, while MR‐Egger, weighted median, and maximum likelihood were used as supplementary methods. The effect of breakfast skipping on CHD and MI in both CARDIoGRAMplusC4D and FinnGen cohorts was assessed, and the results were integrated using meta‐analysis. Quality control tests showed no heterogeneity or horizontal pleiotropy in IVs. After conducting a meta‐analysis of the MR results from the IVW method under strict IV screening thresholds, breakfast skipping significantly increases the risk of CHD [odds ratio (OR) = 1.358, p = 3.95E−02] and MI (OR = 1.449, p = 4.17E−02). Similarly, meta‐analysis of the IVW results under lenient IV screening thresholds also demonstrated the detrimental effects of breakfast skipping on CHD (OR = 1.198, p = 5.55E−03) and MI (OR = 1.378, p = 4.08E−05). Three other MR methods showed parallel results to IVW (OR > 1). Overall, the present study demonstrates that breakfast skipping significantly increases the risk of CHD and MI. Therefore, maintaining a high‐quality breakfast intake can be considered an essential primary prevention measure for CHD and MI.
- Open Access
- 7 March 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (10) , e41737
Exploring the causal relationship between PAH and some autoimmune diseases using bidirectional Mendelian randomization analyses
The causal association between pulmonary arterial hypertension (PAH) and autoimmune diseases remains uncertain. This study aimed to assess the causal associations between PAH and autoimmune diseases using bidirectional Mendelian randomization (MR) analyses. Genome-wide association summary statistics for PAH, asthma, myasthenia gravis, rheumatoid arthritis (RA), systemic lupus erythematosus, and type 1 diabetes mellitus were obtained from publicly accessible databases. The primary MR approach used was the inverse variance weighted method. Sensitivity analyses were conducted to test the robustness of the MR findings, including tests for heterogeneity, horizontal pleiotropy, and leave-one-out analysis, ensuring the reliability and validity of the results. Ultimately, transcriptome analysis was used for GO, KEGG enrichment analysis and protein interaction network. Bidirectional Mendelian randomization analysis found a causal relationship between PAH and RA (OR [95% CI] > 1; P < .05). Enrichment analysis further revealed the common molecular mechanisms of these 2 diseases, especially the dysfunction of chemokine pathway and other inflammation-related signaling pathways. Additionally, the study uncovered the core genes within the co-morbidity-associated protein–protein interaction network, including CCL5, CCL9, and VCAM1. Transcription factor (TF) network analysis showed that TFs such as GATA1, JUN and RELA were significantly up-regulated in PAH, and they play a key role in regulating cell proliferation and immune response. The study found a bidirectional positive causal link between PAH and RA. Dysregulation of the chemokine pathway and other inflammation-related signaling pathways may be momentous factors driving the progression of PAH and RA.
- 7 March 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (10) , e41737
Open AccessExploring the causal relationship between PAH and some autoimmune diseases using bidirectional Mendelian randomization analyses
The causal association between pulmonary arterial hypertension (PAH) and autoimmune diseases remains uncertain. This study aimed to assess the causal associations between PAH and autoimmune diseases using bidirectional Mendelian randomization (MR) analyses. Genome-wide association summary statistics for PAH, asthma, myasthenia gravis, rheumatoid arthritis (RA), systemic lupus erythematosus, and type 1 diabetes mellitus were obtained from publicly accessible databases. The primary MR approach used was the inverse variance weighted method. Sensitivity analyses were conducted to test the robustness of the MR findings, including tests for heterogeneity, horizontal pleiotropy, and leave-one-out analysis, ensuring the reliability and validity of the results. Ultimately, transcriptome analysis was used for GO, KEGG enrichment analysis and protein interaction network. Bidirectional Mendelian randomization analysis found a causal relationship between PAH and RA (OR [95% CI] > 1; P < .05). Enrichment analysis further revealed the common molecular mechanisms of these 2 diseases, especially the dysfunction of chemokine pathway and other inflammation-related signaling pathways. Additionally, the study uncovered the core genes within the co-morbidity-associated protein–protein interaction network, including CCL5, CCL9, and VCAM1. Transcription factor (TF) network analysis showed that TFs such as GATA1, JUN and RELA were significantly up-regulated in PAH, and they play a key role in regulating cell proliferation and immune response. The study found a bidirectional positive causal link between PAH and RA. Dysregulation of the chemokine pathway and other inflammation-related signaling pathways may be momentous factors driving the progression of PAH and RA.